New updates have been reported about Autoimmunity BioSolutions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Autoimmunity BioSolutions (ABS) has closed a $1 million seed extension, lifting total seed financing to $3.1 million and providing runway to hit key preclinical milestones for its immuno-corrective autoimmune therapy platform. The round was led by Eos BioInnovation with continued backing from existing investors and the addition of NewTech Investment Holdings, deepening family office participation and signaling durable support for ABS’s strategy.
Management plans to deploy the new capital into animal model studies and analysis of patient biospecimens in rheumatoid arthritis, its lead indication, to further validate its genetically targeted approach focused on normalizing elevated soluble IL7 receptor (sIL7R). ABS has identified a common genetic variant present in roughly half the population that drives a two- to three-fold increase in sIL7R, which is linked to more severe disease, faster progression, and weaker response to standard-of-care in multiple autoimmune conditions, including rheumatoid arthritis, lupus nephritis, and type 1 diabetes, positioning the company to address a sizable refractory patient subset and potentially partner with existing immunology franchises.